The early-stage human trial data of the COVID-19 vaccine that has been developed in a joint collaboration between Oxford University and British-Swedish drugmaker AstraZeneca will be released on July 20.
The data, which has been widely anticipated, will be published in British peer-reviewed medical journal the Lancet. The Oxford vaccine, also known as ChAdOx1 nCoV-19, was developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford.
The vaccine uses a weakened version of chimpanzee adenovirus as a vector, infused with the genetic material of SARS-CoV-2 spike protein.
Adenovirus is a benign virus that causes the common cold, and so the safety of the vaccine is assured. The Chimpanzee adenovirus is used to help circumvent the problem of pre-existing immunity encountered with other human adenovirus vectors.